Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760993 | 0.82 | PNMT (0.45) | PNMTKCNA5CES2ALDH1A1L3MBTL1 | |
| SCHEMBL17045040 | 0.79 | PNMT (0.53) | PNMTCES2IDO1TDO2ACP3 | |
| SCHEMBL17045031 | 0.79 | PNMT (0.53) | PNMTCES2IDO1TDO2ACP3 | |
| SCHEMBL17045032 | 0.79 | PNMT (0.53) | PNMTCES2IDO1TDO2ACP3 | |
| SCHEMBL5203460 | 0.77 | PNMT (0.40) | PNMTKCNA5CES2IDO1TDO2 | |
| SCHEMBL7502772 | 0.76 | PNMT (0.42) | PNMTKCNA5CES2IDO1TDO2 | |
| SCHEMBL24017114 | 0.74 | PNMT (0.59) | PNMTCES2IDO1TDO2ACP3 | |
| SCHEMBL29897739 | 0.74 | PNMT (0.59) | PNMTCES2IDO1TDO2ACP3 | |
| SCHEMBL15137235 | 0.74 | PNMT (0.59) | PNMTCES2IDO1TDO2ACP3 | |
| SCHEMBL8954497 | 0.72 | HTR2A (0.59) | PNMTCES2IDO1TDO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109803-B1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1414443-B1 | BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1414443-A4 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6852727-B2 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
| US-6767908-B2 | TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS. | MERCK & CO., INC | 2004-07-27 | — | — | US | disclosed |
| EP-1414443-A1 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | Merck & Co., Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1196169-A4 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2003011285-A1 | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1109803-A4 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2002-10-29 | — | — | EP | disclosed |
| EP-1196169-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| US-20020026056-A1 | Substituted imidazoles having cytokine inhibitory activity | MERCK SHARP & DOHME CORP. | 2002-02-28 | — | — | US | disclosed |
| US-6291457-B1 | SUBSTITUTED IMIDAZOLE COMPOUNDS | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1109803-A1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6207687-B1 | USEFUL FOR TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS | MERCK & CO., INC. | 2001-03-27 | — | — | US | disclosed |
| WO-2001001988-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000006563-A1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026056-A1 | Substituted imidazoles having cytokine inhibitory activity | IL1A, IL2, IL1B | PNMT 4512/4885KCNA5 3648/4885CES2 4154/4885 |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | PNMT 2772/4885KCNA5 1158/4885CES2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.